A carregar...
Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US
Objective: To estimate the budget impact of avelumab as a treatment option for patients with treatment-naïve first-line (1L) and previously treated second-line or later (2L+) metastatic Merkel cell carcinoma (mMCC) in the US. Methods: A budget impact model was developed to evaluate the addition of a...
Na minha lista:
| Publicado no: | Clinicoecon Outcomes Res |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6535410/ https://ncbi.nlm.nih.gov/pubmed/31190927 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S202642 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|